Jupiter Neurosciences, Inc. has a market cap of $131.5 million.
Dominari Securities and Revere Securities are managing their IPO.
Jupiter Neurosciences, founded in 2016, focuses on developing a unique drug, JOTROL, to treat neuro-inflammation. They partnered with Aquanova AG to create a formulation aimed at enhancing the effectiveness of resveratrol, a compound known for its health benefits.
JOTROL is a softgel capsule containing 100mg of resveratrol. Pre-clinical tests show that it has higher bioavailability than traditional resveratrol products. A Phase I study in healthy volunteers was completed, and the results will guide future clinical trials.
They plan to focus on rare diseases, particularly Mucopolysaccharidoses Type 1 and Parkinson’s Disease. The company aims to use funds from the IPO for a Phase II trial in Parkinson’s patients and to expand operations in Southeast Asia.
Jupiter recently demonstrated promising results in animal models for Parkinson’s and has attracted interest from Asian organizations. They believe high doses of resveratrol can be achieved without gastrointestinal side effects through JOTROL.
Located in Jupiter, Florida, the company has grown to 4 employees. For inquiries, contact them at (561) 406-6154 or visit their website.
Receive News & Ratings for Jupiter Neurosciences Inc. Daily – Subscribe for a daily summary of news and ratings for Jupiter Neurosciences Inc. and similar companies with MarketBeat.com’s FREE daily email newsletter.
`
